James A Mcswiggen from Arvada, CO, age 69

Us Patents

Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
view source
US Patent:

6346398, Feb 12, 2002
Filed:

Jan 11, 1996
Appl. No.:

08/584040
Inventors:

Pamela Pavco - Lafayette CO
James McSwiggen - Boulder CO
Daniel Stinchcomb - Boulder CO
Jaime Escobedo - Alamo CA
Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO
International Classification:

C12Q 168
US Classification:

435 9131, 435 6, 435 911, 435325, 435375, 514 44, 536 231, 536 245, 536 232
Abstract:

Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Nucleic Acid Encoding Delta-9 Desaturase
view source
US Patent:

6350934, Feb 26, 2002
Filed:

Jul 12, 1996
Appl. No.:

08/679645
Inventors:

Michael G. Zwick - Loveland CO
Brent E. Edington - Boulder CO
James A. McSwiggen - Boulder CO
Patricia Ann Owens Merlo - Carmel IN
Lining Guo - Brownsburg IN
Thomas A. Skokut - Carmel IN
Scott A. Young - Indianapolis IN
Otto Folkerts - Carmel IN
Donald J. Merlo - Carmel IN
Assignee:

Ribozyme Pharmaceuticals, Inc. - Indianapolis IN
DowElanco - Boulder CO
International Classification:

C12N 504
US Classification:

800281, 800278, 800286, 800287, 800292, 800293, 800294, 800300, 8003201, 435412, 435419, 4353201, 435469, 435470, 536 232, 536 236
Abstract:

The present invention relates to nucleic acid molecules encoding delta 9 desaturase gene, and expression vectors, plant cells, and transgenic plants expressing delta 9 desaturase nucleic acid. The nucleic acid molecules of the present invention can be used, for example, to decrease delta 9 desaturase activity in plant cells, resulting in decreased unsaturated fatty acid production.

Ribozyme Treatment Of Diseases Or Conditions Related To Levels Of Nf- B
view source
US Patent:

6410224, Jun 25, 2002
Filed:

Dec 23, 1996
Appl. No.:

08/777916
Inventors:

Dan T. Stinchcomb - Boulder CO
Kenneth G. Draper - Boulder CO
James McSwiggen - Boulder CO
Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO
International Classification:

C07H 2104
US Classification:

435 6, 435 9131, 435325, 435366, 435375, 536245
Abstract:

Enzymatic RNA molecules which cleave rel A mRNA.

Ribozyme Treatment Of Diseases Or Conditions Related To Levels Of Intercellular Adhesion Molecule-1 (Cam-1)
view source
US Patent:

6436644, Aug 20, 2002
Filed:

Jun 7, 2000
Appl. No.:

09/589628
Inventors:

Susan Grimm - Boulder CO
Dan T. Stinchcomb - Boulder CO
James McSwiggen - Boulder CO
Sean Sullivan - Boulder CO
Kenneth G. Draper - Boulder CO
Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO
International Classification:

C07H 2104
US Classification:

435 6, 435 911, 435325, 435375, 536245
Abstract:

The present invention relates to enzymatic RNA molecules which cleave ICAM-1 mRNA.

Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
view source
US Patent:

6566127, May 20, 2003
Filed:

Aug 10, 1999
Appl. No.:

09/371772
Inventors:

Pamela Pavco - Lafayette CO
James A. McSwiggen - Boulder CO
Dan T. Stinchcomb - Fort Collins CO
Jaime Escobedo - Alamo CA
Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO
Chiron Corporation - Emeryville CA
International Classification:

C12N 500
US Classification:

435325, 435 9131, 536 245
Abstract:

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Base-Modified Enzymatic Nucleic Acid
view source
US Patent:

6528639, Mar 4, 2003
Filed:

Mar 3, 1998
Appl. No.:

09/034113
Inventors:

Nassim Usman - Boulder CO
Leonid Beigelman - Longmont CO
James McSwiggen - Boulder CO
Alex Karpeisky - Boulder CO
Assignee:

Ribozyme Pharmaceuticals, Inc. - Boulder CO
International Classification:

C07H 2104
US Classification:

536 245, 435 911, 435 913, 435 9131, 536 231, 536 232, 536 241, 536 243, 536 2431, 536 2433
Abstract:

Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.

Enzymatic Nucleic Acid Treatment Of Diseases Of Conditions Related To Levels Of Epidermal Growth Factor Receptors
view source
US Patent:

6623962, Sep 23, 2003
Filed:

Sep 22, 1999
Appl. No.:

09/401063
Inventors:

Saghir Akhtar - Birmingham, GB
Patricia Fell - Birmingham, GB
James A. McSwiggen - Boulder CO
Assignee:

Sirna Therapeutics, Inc. - Boulder CO
Aston University - Birmingham
International Classification:

C07H 2104
US Classification:

435375, 435 6, 435 911, 435 913, 536 231, 536 232, 536 243, 536 2431, 536 2433, 536 245
Abstract:

Enzymatic nucleic acid molecules which cleave EGFR RNA.

Nucleic Acid Molecules With Novel Chemical Compositions Capable Of Modulating Gene Expression
view source
US Patent:

6673611, Jan 6, 2004
Filed:

May 25, 2001
Appl. No.:

09/866316
Inventors:

James Thompson - Lafayette CO
Leonid Beigelman - Longmont CO
James McSwiggen - Boulder CO
Alexander Karpeisky - Lafayette CO
Laurent Bellon - Frederick MD
Mark Reynolds - Pleasanton CA
Michael Zwick - Madison WI
Thale Jarvis - Boulder CO
Tod Woolf - Sudbury MA
Peter Haeberli - Berthoud CO
Assignee:

Sirna Therapeutics, Inc. - Boulder CO
International Classification:

C12Q 168
US Classification:

435455, 435 6, 435 911, 435366, 536 231, 536 245
Abstract:

This invention relates to novel chemically-modified nucleic acid molecules having specific formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.

Resumes

Senior Research Fellow, Bioinformatics At Rana Therapeutics, Inc.

view source

Position:

Senior Research Fellow, Bioinformatics at RaNA Therapeutics, Inc., Chief Executive Officer at RNA Society, Owner & Principle Consultant at McSwiggen & Associates Biotech Consulting

Location:

Greater Denver Area

Industry:

Biotechnology

Work:

RaNA Therapeutics, Inc. - Cambridge, MA since 2012
Senior Research Fellow, Bioinformatics
RNA Society since Jan 2011
Chief Executive Officer
McSwiggen & Associates Biotech Consulting since Feb 2009
Owner & Principle Consultant
Quark Pharmaceuticals Jul 2008 - Jan 2009
Senior Director, Nucleic Acid R&D
MDRNA, Inc. Jun 2008 - Jul 2008
Vice President, Biochemistry & Bioinformatics

Education:

University of Oregon 1979 - 1986
PhD, Biochemistry University of Wisconsin-Madison 1974 - 1979
BS w/Honors, Molecular Biology

Chief Executive Officer

view source

Location:

19395 west 94Th Ave, Arvada, CO 80001

Industry:

Biotechnology

Work:

McSwiggen & Associates Biotech Consulting since Feb 2009
Owner & Principle Consultant
RNA Society since Jan 2011
Chief Executive Officer
RaNA Therapeutics, Inc. - Cambridge, MA Jan 2012 - Jun 2013
Senior Research Fellow, Bioinformatics
Quark Pharmaceuticals - Boulder, CO Jul 2008 - Jan 2009
Senior Director, Nucleic Acid R&D
MDRNA, Inc. - Bothell, WA Jun 2008 - Jul 2008
Vice President, Biochemistry & Bioinformatics

Education:

University of Oregon 1979 - 1986
PhD, Biochemistry University of Wisconsin-Madison 1974 - 1979
BS w/Honors, Molecular Biology

Skills:

Biotechnology
Biochemistry
Drug Discovery
Drug Development
Bioinformatics
R&D
Rnai
Laboratory
Biomarker Discovery
Sequence Analysis
Sirna
Drug Design
Patents
Rna
Nucleic Acid
Lifesciences
Data Analysis
Statistics
Analysis
Enzyme Kinetics

Interests:

Hiking
Travel
Biking